Petros Pharmaceuticals, Inc. (NASDAQ:PTPI – Get Free Report) shares fell 5.8% during mid-day trading on Friday . The stock traded as low as $0.32 and last traded at $0.33. 6,130,722 shares changed hands during trading, an increase of 1,045% from the average session volume of 535,337 shares. The stock had previously closed at $0.35.
Petros Pharmaceuticals Stock Performance
The stock’s 50-day moving average is $0.32 and its 200-day moving average is $0.37. The company has a debt-to-equity ratio of 1.58, a current ratio of 0.85 and a quick ratio of 0.74. The stock has a market cap of $3.30 million, a price-to-earnings ratio of -0.07 and a beta of 1.99.
Petros Pharmaceuticals Company Profile
Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).
Further Reading
- Five stocks we like better than Petros Pharmaceuticals
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Dave & Buster’s: Is It Time to Make Another Play on This Stock?
- Why Invest in 5G? How to Invest in 5G Stocks
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Texas Instruments: The Old-School Tech Titan Still Delivering
Receive News & Ratings for Petros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
